Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study

OBJECTIVE: Assess golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS). METHODS: 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Deodhar, Atul, Braun, Jürgen, Inman, Robert D, van der Heijde, Désirée, Zhou, Yiying, Xu, Stephen, Han, Chenglong, Hsu, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392310/
https://www.ncbi.nlm.nih.gov/pubmed/25387477
http://dx.doi.org/10.1136/annrheumdis-2014-205862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392310/
https://www.ncbi.nlm.nih.gov/pubmed/25387477
http://dx.doi.org/10.1136/annrheumdis-2014-205862

Ejemplares similares